Cambridge, MA-based Stromedix has landed $25 million in a Series B round of venture capital. The company's lead drug is STX-100, a humanized monoclonal antibody which Stromedix is developing for chronic allograft dysfunction, a fibrotic condition that is a leading cause of graft loss in kidney transplant patients. There are no approved therapies for the condition. A Phase I trial of the drug kicked off earlier this year. The round was led by New Leaf Venture Partners; Bessemer Venture Partners, Red Abbey Venture Partners, Atlas Venture, Frazier Healthcare Ventures also participated.
- check out this press release
Related Article:
MAbs are hottest segment of biotech industry. Report